Reports of Side Effects from Bayer’s Xarelto Grow – Spiegel

Reports of Side Effects from Bayer’s Xarelto Grow - Spiegel
Reports of Side Effects from Bayer’s Xarelto Grow - Spiegel

Xarelto is used to reduce the risk of stroke and blood clots in people with atrial fibrillation, not caused by a heart valve problem. There is limited information on how effective it is compared to warfarin (coumadin). The FDA approved it’s use in the US in November 2011.

A German magazine, Der Spiegel,  published an article about the extraordinary amount of reported side effects in Germany from the drug Xarelto. They state:

  • In 2013, for 8 months, 968 cases of (suspected) side effects, including 72 deaths.
  • In 2012, for the full year, 750 cases of side-effects, including 58 cases of death.

Bayer projects $2b in sales for Xarelto. Via Reuters

– MedShadow Staff

DISCLAIMER: MedShadow provides information and resources related to medications, their effects, and potential side effects. However, it is important to note that we are not a substitute for professional medical advice, diagnosis, or treatment. The content on our site is intended for educational and informational purposes only. Individuals dealing with medical conditions or symptoms should seek guidance from a licensed healthcare professional, such as a physician or pharmacist, who can provide personalized medical advice tailored to their specific circumstances.

While we strive to ensure the accuracy and reliability of the information presented on MedShadow, we cannot guarantee its completeness or suitability for any particular individual's medical needs. Therefore, we strongly encourage users to consult with qualified healthcare professionals regarding any health-related concerns or decisions. By accessing and using MedShadow, you acknowledge and agree that the information provided on the site is not a substitute for professional medical advice and that you should always consult with a qualified healthcare provider for any medical concerns.

Was This Article Helpful?

Show Comments (0)
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments